GT Biopharma, Inc. (GTBP) stock
GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.18−0.25 (-7.29%)
Close on Nov 19, 2026Market cap $143.45MP/E –Yield –
GT Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
GT Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$16.34M. For fiscal 2025 it was -$12.42M. The highest annual figure on record is $16.06M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.42M | – |
| FY2024 | Dec 31, 2024 | -$14.36M | – |
| FY2023 | Dec 31, 2023 | -$13.58M | – |
| FY2022 | Dec 31, 2022 | -$21.26M | – |
| FY2021 | Dec 31, 2021 | -$57.52M | – |
| FY2020 | Dec 31, 2020 | -$6.76M | -142.1% |
| FY2019 | Dec 31, 2019 | $16.06M | – |
| FY2018 | Dec 31, 2018 | -$250.07M | – |
| FY2017 | Dec 31, 2017 | -$135.57M | – |
| FY2016 | Dec 31, 2016 | -$9.37M | – |
| FY2015 | Dec 31, 2015 | -$8.93M | – |
| FY2014 | Dec 31, 2014 | -$2.40M | – |
| FY2013 | Dec 31, 2013 | -$793.00K | – |
| FY2012 | Dec 31, 2012 | -$3.51M | – |
| FY2011 | Dec 31, 2011 | -$3.93M | – |
| FY2010 | Dec 31, 2010 | -$2.50M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.51M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.85M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.38M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.51M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.76M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.67M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.78M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.00M | -2810.5% |
| Q4 FY2020 | Dec 31, 2020 | -$2.19M | -107.0% |
| Q3 FY2020 | Sep 30, 2020 | -$1.95M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.56M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.07M | – |
| Q4 FY2019 | Dec 31, 2019 | $31.25M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.28M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.06M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.09M | – |
| Q3 FY2018 | Sep 30, 2018 | -$234.66M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.16M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.16M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.89M | – |
| Q3 FY2017 | Sep 30, 2017 | -$126.86M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.29M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.54M | – |
| Q4 FY2016 | Dec 31, 2016 | -$822.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.53M | – |
See a number that looks wrong?